Detail akcie Supernus online

Business Summary: Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Supernus Pharmaceuticals Inc revenues decreased 9% to $607.5M. Net income decreased 98% to $1.3M. Revenues reflect Net product sales decrease of 12% to $573.9M. Net income also reflects Pharmaceutical segment loss totaling $5.3M vs. income of $46.1M. Basic Earnings per Share excluding Extraordinary Items decreased from $1.13 to $0.02.